×
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.01 (+0.62%)
AAPL   138.95 (+1.63%)
MSFT   259.63 (+1.09%)
META   160.05 (-0.74%)
GOOGL   2,173.25 (-0.28%)
AMZN   109.50 (+3.10%)
TSLA   679.75 (+0.94%)
NVDA   144.90 (-4.41%)
NIO   21.37 (-1.61%)
BABA   115.95 (+2.00%)
AMD   73.54 (-3.83%)
MU   53.65 (-2.95%)
CGC   2.80 (-1.75%)
T   21.32 (+1.72%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.18 (+1.89%)
AMC   13.47 (-0.59%)
PFE   52.32 (-0.21%)
PYPL   70.74 (+1.29%)
NFLX   180.10 (+2.99%)
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.01 (+0.62%)
AAPL   138.95 (+1.63%)
MSFT   259.63 (+1.09%)
META   160.05 (-0.74%)
GOOGL   2,173.25 (-0.28%)
AMZN   109.50 (+3.10%)
TSLA   679.75 (+0.94%)
NVDA   144.90 (-4.41%)
NIO   21.37 (-1.61%)
BABA   115.95 (+2.00%)
AMD   73.54 (-3.83%)
MU   53.65 (-2.95%)
CGC   2.80 (-1.75%)
T   21.32 (+1.72%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.18 (+1.89%)
AMC   13.47 (-0.59%)
PFE   52.32 (-0.21%)
PYPL   70.74 (+1.29%)
NFLX   180.10 (+2.99%)
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.01 (+0.62%)
AAPL   138.95 (+1.63%)
MSFT   259.63 (+1.09%)
META   160.05 (-0.74%)
GOOGL   2,173.25 (-0.28%)
AMZN   109.50 (+3.10%)
TSLA   679.75 (+0.94%)
NVDA   144.90 (-4.41%)
NIO   21.37 (-1.61%)
BABA   115.95 (+2.00%)
AMD   73.54 (-3.83%)
MU   53.65 (-2.95%)
CGC   2.80 (-1.75%)
T   21.32 (+1.72%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.18 (+1.89%)
AMC   13.47 (-0.59%)
PFE   52.32 (-0.21%)
PYPL   70.74 (+1.29%)
NFLX   180.10 (+2.99%)
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.01 (+0.62%)
AAPL   138.95 (+1.63%)
MSFT   259.63 (+1.09%)
META   160.05 (-0.74%)
GOOGL   2,173.25 (-0.28%)
AMZN   109.50 (+3.10%)
TSLA   679.75 (+0.94%)
NVDA   144.90 (-4.41%)
NIO   21.37 (-1.61%)
BABA   115.95 (+2.00%)
AMD   73.54 (-3.83%)
MU   53.65 (-2.95%)
CGC   2.80 (-1.75%)
T   21.32 (+1.72%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.18 (+1.89%)
AMC   13.47 (-0.59%)
PFE   52.32 (-0.21%)
PYPL   70.74 (+1.29%)
NFLX   180.10 (+2.99%)
NASDAQ:NDRA

ENDRA Life Sciences Stock Forecast, Price & News

$0.23
0.00 (-1.84%)
(As of 07/1/2022 03:58 PM ET)
Add
Compare
Today's Range
$0.22
$0.23
50-Day Range
$0.19
$0.28
52-Week Range
$0.18
$2.22
Volume
2,310 shs
Average Volume
1.67 million shs
Market Capitalization
$10.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

ENDRA Life Sciences Stock Forecast (MarketRank)

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
2,073.9% Upside
$5.00 Price Target
Short Interest
Healthy
0.97% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.82mentions of ENDRA Life Sciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$11.72 K Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.19) to ($0.09) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.00 out of 5 stars

Medical Sector

488th out of 1,429 stocks

Electromedical Equipment Industry

13th out of 30 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive NDRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ENDRA Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

ENDRA Life Sciences logo

About ENDRA Life Sciences (NASDAQ:NDRA)

ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

NDRA Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NDRA
Fax
N/A
Employees
18
Year Founded
N/A

Company Calendar

Last Earnings
11/15/2021
Today
7/01/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+2,073.9%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
1 Analysts

Profitability

Net Income
$-11.23 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.25 per share

Miscellaneous

Free Float
41,311,000
Market Cap
$10.14 million
Optionable
Not Optionable
Beta
1.40














ENDRA Life Sciences Frequently Asked Questions

Should I buy or sell ENDRA Life Sciences stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ENDRA Life Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ENDRA Life Sciences stock.
View analyst ratings for ENDRA Life Sciences
or view top-rated stocks.

What is ENDRA Life Sciences' stock price forecast for 2022?

1 brokerages have issued 12 month price targets for ENDRA Life Sciences' shares. Their NDRA stock forecasts range from $5.00 to $5.00. On average, they expect ENDRA Life Sciences' stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 2,073.9% from the stock's current price.
View analysts' price targets for ENDRA Life Sciences
or view top-rated stocks among Wall Street analysts.

How has ENDRA Life Sciences' stock price performed in 2022?

ENDRA Life Sciences' stock was trading at $0.6918 at the beginning of the year. Since then, NDRA shares have decreased by 66.8% and is now trading at $0.23.
View the best growth stocks for 2022 here
.

When is ENDRA Life Sciences' next earnings date?

ENDRA Life Sciences is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for ENDRA Life Sciences
.

How were ENDRA Life Sciences' earnings last quarter?

ENDRA Life Sciences Inc. (NASDAQ:NDRA) issued its quarterly earnings results on Monday, November, 15th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01. During the same quarter in the previous year, the firm earned ($0.15) earnings per share.
View ENDRA Life Sciences' earnings history
.

Who are ENDRA Life Sciences' key executives?

ENDRA Life Sciences' management team includes the following people:
  • Mr. Francois Michelon, Chairman, Pres & CEO (Age 56, Pay $511.64k)
  • Mr. Michael Thornton, Chief Technology Officer (Age 54, Pay $358.75k) (LinkedIn Profile)
  • Mr. Renaud Bertrand Maloberti, Chief Commercial Officer (Age 53, Pay $321.53k)
  • Dr. Jonathan Behr, Co-Founder
  • Ms. Irina Pestrikova, Sr. Director of Fin. & Sec. (Age 35)
  • Mr. Steve Freeman, HR Leader

What other stocks do shareholders of ENDRA Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ENDRA Life Sciences investors own include Advanced Micro Devices (AMD), Trevena (TRVN), VBI Vaccines (VBIV), Ampio Pharmaceuticals (AMPE), Bionano Genomics (BNGO), OPKO Health (OPK), TherapeuticsMD (TXMD), Vista Gold (VGZ), electroCore (ECOR) and Genocea Biosciences (GNCA).

When did ENDRA Life Sciences IPO?

(NDRA) raised $10 million in an initial public offering on Friday, February 3rd 2017. The company issued 2,000,000 shares at a price of $5.00-$5.50 per share. Dougherty & Company and Dawson James Securities acted as the underwriters for the IPO.

What is ENDRA Life Sciences' stock symbol?

ENDRA Life Sciences trades on the NASDAQ under the ticker symbol "NDRA."

How do I buy shares of ENDRA Life Sciences?

Shares of NDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ENDRA Life Sciences' stock price today?

One share of NDRA stock can currently be purchased for approximately $0.23.

How much money does ENDRA Life Sciences make?

ENDRA Life Sciences (NASDAQ:NDRA) has a market capitalization of $10.14 million. The company earns $-11.23 million in net income (profit) each year or ($0.280010) on an earnings per share basis.

How many employees does ENDRA Life Sciences have?

ENDRA Life Sciences employs 18 workers across the globe.

How can I contact ENDRA Life Sciences?

ENDRA Life Sciences' mailing address is 3600 GREEN COURT SUITE 350, ANN ARBOR MI, 48105. The official website for ENDRA Life Sciences is www.endrainc.com. The company can be reached via phone at (734) 335-0468 or via email at [email protected].

This page (NASDAQ:NDRA) was last updated on 7/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.